Use of B7 costimulatory molecules as adjuvants in a prime-boost vaccination against Visna/Maedi ovine lentivirus

Vaccine

Volumn 27, Issue 34, 2009, Pages 4591-4600

  de Andres X ^a   Reina, R ^a,b   Ciriza, J ^a,c   Crespo, H ^a   Glaria, I ^a   Ramirez H ^a   Grillo M J ^a   Perez M M ^d   Andresdottir V ^e   Rosati, S ^b   Suzan Monti, M ^f   Lujan L ^d   Blacklaws, B A ^g   Harkiss, G D ^h   de Andres D ^a   Amorena, B ^a  

^a PUBLIC UNIVERSITY OF NAVARRE   (Spain)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF ZARAGOZA   (Spain)

^e UNIVERSITY OF ICELAND   (Iceland)

^f AIX MARSEILLE UNIVERSITY   (France)

^g UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^h UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

B7 costimulatory molecules; DNA vaccination; Sheep; Small ruminant lentivirus

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN; GAG PROTEIN; VIRUS ENVELOPE PROTEIN; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GENE GUN IMMUNIZATION; IMMUNE RESPONSE; IMMUNIZATION; INFECTION PREVENTION; LYMPHOCYTE PROLIFERATION; LYMPHOID TISSUE; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RECOMBINANT PLASMID; SHEEP; T LYMPHOCYTE ACTIVATION; VACCINATION; VACCINIA VIRUS; VIRUS GENE; VIRUS INFECTION; VIRUS LOAD; VISNA VIRUS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, CD80; ANTIGENS, CD86; CD4-POSITIVE T-LYMPHOCYTES; GENE PRODUCTS, ENV; GENE PRODUCTS, GAG; GENETIC VECTORS; IMMUNIZATION, SECONDARY; MALE; PNEUMONIA, PROGRESSIVE INTERSTITIAL, OF SHEEP; SHEEP; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, DNA; VACCINIA VIRUS; VIRAL VACCINES; VISNA-MAEDI VIRUS;

EID: 67649487906     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.05.080     Document Type: Article

References (60)

1. Narayan O., and Clements J.E. Biology and pathogenesis of lentiviruses. J Gen Virol 70 July (Part 7) (1989) 1617-1639
2. Brodie S.J., Marcom K.A., Pearson L.D., Anderson B.C., de la Concha-Bermejillo A., Ellis J.A., et al. Effects of virus load in the pathogenesis of lentivirus-induced lymphoid interstitial pneumonia. J Infect Dis 166 September (3) (1992) 531-541
3. Eriksson K., McInnes E., Ryan S., Tonks P., McConnell I., and Blacklaws B. CD4(+) T-cells are required for the establishment of maedi-visna virus infection in macrophages but not dendritic cells in vivo. Virology 258 June (2) (1999) 355-364
4. Nathanson N., Panitch H., Palsson P.A., Petursson G., and Georgsson G. Pathogenesis of visna. II. Effect of immunosuppression upon early central nervous system lesions. Lab Invest 35 November (5) (1976) 444-451
5. Ravazzolo A.P., Nenci C., Vogt H.R., Waldvogel A., Obexer-Ruff G., Peterhans E., et al. Viral load, organ distribution, histopathological lesions, and cytokine mRNA expression in goats infected with a molecular clone of the caprine arthritis encephalitis virus. Virology 350 June (1) (2006) 116-127
6. Zhang Z., Watt N.J., Hopkins J., Harkiss G., and Woodall C.J. Quantitative analysis of maedi-visna virus DNA load in peripheral blood monocytes and alveolar macrophages. J Virol Methods 86 April (1) (2000) 13-20
7. Knowles Jr. D., Cheevers W., McGuire T., Stem T., and Gorham J. Severity of arthritis is predicted by antibody response to gp135 in chronic infection with caprine arthritis-encephalitis virus. J Virol 64 May (5) (1990) 2396-2398
8. Lujan L., Begara I., Collie D., and Watt N.J. Ovine lentivirus (maedi-visna virus) protein expression in sheep alveolar macrophages. Vet Pathol 31 November (6) (1994) 695-703
9. Reina R., Berriatua E., Lujan L., Juste R., Sanchez A., de Andres D., et al. Prevention strategies against small ruminant lentiviruses: an update. Vet J 182 October (1) (2009) 31-37
10. Donnelly J.J., Wahren B., and Liu M.A. DNA vaccines: progress and challenges. J Immunol 175 July (2) (2005) 633-639
11. Cheevers W.P., Snekvik K.R., Trujillo J.D., Kumpula-McWhirter N.M., Pretty On Top K.J., and Knowles D.P. Prime-boost vaccination with plasmid DNA encoding caprine-arthritis encephalitis lentivirus env and viral SU suppresses challenge virus and development of arthritis. Virology 306 February (1) (2003) 116-125
12. McGuire T.C., Adams D.S., Johnson G.C., Klevjer-Anderson P., Barbee D.D., and Gorham J.R. Acute arthritis in caprine arthritis-encephalitis virus challenge exposure of vaccinated or persistently infected goats. Am J Vet Res 47 March (3) (1986) 537-540
13. Nenci C., Zahno M.L., Vogt H.R., Obexer-Ruff G., Doherr M.G., Zanoni R., et al. Vaccination with a T-cell-priming Gag peptide of caprine arthritis encephalitis virus enhances virus replication transiently in vivo. J Gen Virol 88 May (Part 5) (2007) 1589-1593
14. Gonzalez B., Reina R., Garcia I., Andres S., Glaria I., Alzueta M., et al. Mucosal immunization of sheep with a Maedi-Visna virus (MVV) env DNA vaccine protects against early MVV productive infection. Vaccine 23 July (34) (2005) 4342-4352
15. Niesalla H., de Andres X., Barbezange C., Fraisier C., Reina R., Arnarson H., et al. Systemic DNA immunization against ovine lentivirus using particle-mediated epidermal delivery and modified vaccinia Ankara encoding the gag and/or env genes. Vaccine 27 January (2) (2009) 260-269
16. Reina R., Barbezange C., Niesalla H., de Andres X., Arnarson H., Biescas E., et al. Mucosal immunization against ovine lentivirus using PEI-DNA complexes and modified vaccinia Ankara encoding the gag and/or env genes. Vaccine 26 August (35) (2008) 4494-4505
17. Cutlip R.C., Lehmkuhl H.D., Brogden K.A., and Schmerr M.J. Failure of experimental vaccines to protect against infection with ovine progressive pneumonia (maedi-visna) virus. Vet Microbiol 13 March (3) (1987) 201-204
18. Nathanson N., Martin J.R., Georgsson G., Palsson P.A., Lutley R.E., and Petursson G. The effect of post-infection immunization on the severity of experimental visna. J Comp Pathol 91 April (2) (1981) 185-191
19. Petursson G., Matthiasdottir S., Svansson V., Andresdottir V., Georgsson G., Martin A.H., et al. Mucosal vaccination with an attenuated maedi-visna virus clone. Vaccine 23 May (24) (2005) 3223-3228
20. Torsteinsdottir S., Carlsdottir H.M., Svansson V., Matthiasdottir S., Martin A.H., and Petursson G. Vaccination of sheep with Maedi-visna virus gag gene and protein, beneficial or harmful?. Vaccine 25 September (37-38) (2007) 6713-6720
21. Amara R.R., Patel K., Niedziela G., Nigam P., Sharma S., Staprans S.I., et al. A combination DNA and attenuated simian immunodeficiency virus vaccine strategy provides enhanced protection from simian/human immunodeficiency virus-induced disease. J Virol 79 December (24) (2005) 15356-15367
22. McAdam A.J., Schweitzer A.N., and Sharpe A.H. The role of B7 co-stimulation in activation and differentiation of CD4+ and CD8+ T cells. Immunol Rev 165 October (1998) 231-247
23. Mueller D.L., Jenkins M.K., and Schwartz R.H. Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu Rev Immunol 7 (1989) 445-480
24. Freeman G.J., Freedman A.S., Segil J.M., Lee G., Whitman J.F., and Nadler L.M. B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells. J Immunol 143 October (8) (1989) 2714-2722
25. Freeman G.J., Gray G.S., Gimmi C.D., Lombard D.B., Zhou L.J., White M., et al. Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7. J Exp Med 174 September (3) (1991) 625-631
26. Azuma M., Ito D., Yagita H., Okumura K., Phillips J.H., Lanier L.L., et al. B70 antigen is a second ligand for CTLA-4 and CD28. Nature 366 November (6450) (1993) 76-79
27. Freeman G.J., Gribben J.G., Boussiotis V.A., Ng J.W., Restivo Jr. V.A., Lombard L.A., et al. Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science 262 November (5135) (1993) 909-911
28. Collins A.V., Brodie D.W., Gilbert R.J., Iaboni A., Manso-Sancho R., Walse B., et al. The interaction properties of costimulatory molecules revisited. Immunity 17 August (2) (2002) 201-210
29. Linsley P.S., Greene J.L., Brady W., Bajorath J., Ledbetter J.A., and Peach R. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1 December (9) (1994) 793-801
30. Terzo E.A., Alzueta M., Amorena B., de Andres D.F., and de la Lastra J.M. Molecular cloning and mRNA tissue-expression of two isoforms of the ovine costimulatory molecule CD80 (B7-1). Vet Immunol Immunopathol 103 January (1-2) (2005) 9-19
31. Terzo E.A., de Villarreal M.P., Mick V., Munoz F., Amorena B., de Andres D., et al. Molecular cloning of multiple forms of the ovine B7-2 (CD86) costimulatory molecule. Vet Immunol Immunopathol 114 November (1-2) (2006) 149-158
32. Reina R., Glaria I., Benavides J., de Andres X., Crespo H., Solano C., et al. Association of CD80 and CD86 expression levels with disease status of Visna/Maedi virus infected sheep. Viral Immunol 20 December (4) (2007) 609-622
33. Sargan D.R., Bennet I.D., Cousens C., Roy D.J., Blacklaws B.A., Dalziel R.G., et al. Nucleotide sequence of EV1, a British isolate of maedi-visna virus. J Gen Virol 72 August (Part 8) (1991) 1893-1903
34. Fraisier C., Arnarson H., Barbezange C., Andresdottir V., Carrozza M.L., De Andres D., et al. Expression of the gp150 maedi visna virus envelope precursor protein by mammalian expression vectors. J Virol Methods 146 December (1-2) (2007) 363-367
35. Watkins C., Hopkins J., and Harkiss G. Reporter gene expression in dendritic cells after gene gun administration of plasmid DNA. Vaccine 23 July (33) (2005) 4247-4256
36. Singh I., McConnell I., and Blacklaws B. Immune response to individual maedi-visna virus gag antigens. J Virol 80 January (2) (2006) 912-919
37. Bird P., Blacklaws B., Reyburn H.T., Allen D., Hopkins J., Sargan D., et al. Early events in immune evasion by the lentivirus maedi-visna occurring within infected lymphoid tissue. J Virol 67 September (9) (1993) 5187-5197
38. McNeilly T.N., Tennant P., Lujan L., Perez M., and Harkiss G.D. Differential infection efficiencies of peripheral lung and tracheal tissues in sheep infected with Visna/maedi virus via the respiratory tract. J Gen Virol 88 February (Part 2) (2007) 670-679
39. Saman E., Van Eynde G., Lujan L., Extramiana B., Harkiss G., Tolari F., et al. A new sensitive serological assay for detection of lentivirus infections in small ruminants. Clin Diagn Lab Immunol 6 September (5) (1999) 734-740
40. Germain K. Les infections à lentivirus chez la chèvre et le mouton: ètude des interactions entre sous-type viral et espèce animale; 2007.
41. Genesca M., McChesney M.B., and Miller C.J. Antiviral CD8+ T cells in the genital tract control viral replication and delay progression to AIDS after vaginal SIV challenge in rhesus macaques immunized with virulence attenuated SHIV 89.6. J Intern Med 265 January (1) (2009) 67-77
42. Hansen S.G., Vieville C., Whizin N., Coyne-Johnson L., Siess D.C., Drummond D.D., et al. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med 15 March (3) (2009) 293-299
43. Masopust D. Developing an HIV cytotoxic T-lymphocyte vaccine: issues of CD8 T-cell quantity, quality and location. J Intern Med 265 January (1) (2009) 125-137
44. McGuire T.C., Fraser D.G., and Mealey R.H. Cytotoxic T lymphocytes in protection against equine infectious anemia virus. Anim Health Res Rev 5 December (2) (2004) 271-276
45. Cheevers W.P., Beyer J.C., and Hotzel I. Plasmid DNA encoding caprine interferon gamma inhibits antibody response to caprine arthritis-encephalitis virus (CAEV) surface protein encoded by a co-administered plasmid expressing CAEV env and tat genes. Vaccine 19 April (23-24) (2001) 3209-3215
46. Iwasaki A., Stiernholm B.J., Chan A.K., Berinstein N.L., and Barber B.H. Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines. J Immunol 158 May (10) (1997) 4591-4601
47. Kim J.J., Bagarazzi M.L., Trivedi N., Hu Y., Kazahaya K., Wilson D.M., et al. Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule genes. Nat Biotechnol 15 July (7) (1997) 641-646
48. Tsuji T., Hamajima K., Ishii N., Aoki I., Fukushima J., Xin K.Q., et al. Immunomodulatory effects of a plasmid expressing B7-2 on human immunodeficiency virus-1-specific cell-mediated immunity induced by a plasmid encoding the viral antigen. Eur J Immunol 27 March (3) (1997) 782-787
49. Santra S., Barouch D.H., Jackson S.S., Kuroda M.J., Schmitz J.E., Lifton M.A., et al. Functional equivalency of B7-1 and B7-2 for costimulating plasmid DNA vaccine-elicited CTL responses. J Immunol 165 December (12) (2000) 6791-6795
50. Corr M., Tighe H., Lee D., Dudler J., Trieu M., Brinson D.C., et al. Costimulation provided by DNA immunization enhances antitumor immunity. J Immunol 159 November (10) (1997) 4999-5004
51. Kim J.J., Nottingham L.K., Wilson D.M., Bagarazzi M.L., Tsai A., Morrison L.D., et al. Engineering DNA vaccines via co-delivery of co-stimulatory molecule genes. Vaccine 16 November (19) (1998) 1828-1835
52. Barker E., Bossart K.N., Fujimura S.H., and Levy J.A. The role of CD80 and CD86 in enhancing CD8(+) cell suppression of HIV replication. Cell Immunol 196 September (2) (1999) 95-103
53. Kajikawa O., Lairmore M.D., and DeMartini J.C. Analysis of antibody responses to phenotypically distinct lentiviruses. J Clin Microbiol 28 April (4) (1990) 764-770
54. Houwers D.J., and Nauta I.M. Immunoblot analysis of the antibody response to ovine lentivirus infections. Vet Microbiol 19 February (2) (1989) 127-139
55. Andresson O.S., Elser J.E., Tobin G.J., Greenwood J.D., Gonda M.A., Georgsson G., et al. Nucleotide sequence and biological properties of a pathogenic proviral molecular clone of neurovirulent visna virus. Virology 193 March (1) (1993) 89-105
56. Crane S.E., Clements J.E., and Narayan O. Separate epitopes in the envelope of visna virus are responsible for fusion and neutralization: biological implications for anti-fusion antibodies in limiting virus replication. J Virol 62 August (8) (1988) 2680-2685
57. Narayan O., Clements J.E., Griffin D.E., and Wolinsky J.S. Neutralizing antibody spectrum determines the antigenic profiles of emerging mutants of visna virus. Infect Immun 32 June (3) (1981) 1045-1050
58. Hessell A.J., Hangartner L., Hunter M., Havenith C.E., Beurskens F.J., Bakker J.M., et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449 September (7158) (2007) 101-104
59. Cheevers W.P., McGuire T.C., Norton L.K., Cordery-Cotter R., and Knowles D.P. Failure of neutralizing antibody to regulate CAE lentivirus expression in vivo. Virology 196 October (2) (1993) 835-839
60. Bird P., Reyburn H.T., Blacklaws B.A., Allen D., Nettleton P., Yirrell D.L., et al. The restricted IgG1 antibody response to maedi visna virus is seen following infection but not following immunization with recombinant gag protein. Clin Exp Immunol 102 November (2) (1995) 274-280